RAPT Therapeutics Inc

NASDAQ:RAPT   10:48:29 AM EDT
30.82
-0.37 (-1.19%)
Products, Regulatory, Earnings Announcements

Rapt Therapeutics Reports Positive Topline Results From Phase 1B Trial Of Rpt193 Monotherapy In Atopic Dermatitis

Published: 06/14/2021 12:41 GMT
RAPT Therapeutics Inc (RAPT) - Rapt Therapeutics Reports Positive Topline Results From Phase 1b Trial of Rpt193 Monotherapy in Atopic Dermatitis.
Rapt Therapeutics - Further Improvement in Percent Change in Easi, Easi-50 and Viga Observed With Rpt193 Two Weeks After End of Treatment.
Rapt Therapeutics Inc - Rpt193 Was Well Tolerated With No Serious Adverse Events.
Rapt Therapeutics Inc - Plans to Advance Rpt193 to Phase 2b Clinical Trial in Atopic Dermatitis.
Rapt Therapeutics - Patients Treated With Rpt193 Achieved 36.3% Improvement in Easi Score From Baseline Versus 17.0% Improvement in Patients in Placebo Group.
Revenue is expected to be $1.01 Million
Adjusted EPS is expected to be -$0.70

Next Quarter Revenue Guidance is expected to be $0.96 Million
Next Quarter EPS Guidance is expected to be -$0.76

More details on our Analysts Page.